Investing in agriculture to reduce human health externalities: a low- and middle-income country perspective

Delia Grace, Program Leader, Animal and Human Health
INTERNATIONAL LIVESTOCK RESEARCH INSTITUTE

Workshop on "Increasing Investments for AMR R&D" Tuesday 28 May 2019, Domaine de Penthes, Geneva












CGIAR on the ground: 15 research centres | more than 70 countries




More than 73% of all antimicrobials sold in the world are used in animals Van Boeckel et al 2017

Around 80% of farmers rely on untrained health providers Grace, 2015






The One Health Argument





Better to control disease in the animal host than human victim

Surveillance and response in animal hosts can reduce costs by 90% (Grace, 2015)







Caveat: a problem of access as well as excess

- Animal disease is a key constraint:
 Billions die each year from preventable & curable disease
- As livestock systems intensify in developing countries, diseases may increase




Annual mortality of African livestock (Around half due to preventable or curable disease)

	Young	Adult
Cattle	22%	6%
Shoat	28%	11%
Poultry	70%	30%

Otte & Chilonda, IAEA

Caveat: what human health externalities?






Health burden of foodborne disease in developing countries is comparable to that of HIV AIDS, TB or malaria

Emerging zoonotic disease events, 1940–2012

Potential Hotspots in US, Western Europe, Brazil, Southeast Asia

Most emerging human diseases come from animals. This map locates zoonotic events over the past 72 years, with recent events (identified by an ILRI-led study in 2012) in blue. Like earlier analyses, the study shows western Europe and western USA are hotspots; recent events, however, show an increasingly higher representation of developing countries.





Grace et al., 2012

Investment case

- How much human AMR comes from agriculture?
- What interventions could reduce use in agriculture?
- What are the costs and benefits of these interventions?
 What are the un-intended consequences?
 Are interventions feasible?
- What effect does the intervention have on human AMR?
- What effect does the intervention have on human and animal well-being?




What we know

	HIC	LMIC
How much AMR from agriculture?	Certainly a little, maybe more	Don't know
Interventions shown to reduce AMU at scale	Yes	No
Interventions are affordable	Yes	Don't know
Interventions are feasible	Yes	Maybe not
Un-intended negative consequences	Likely small	May be large
Interventions appreciably reduce AMR in people	Don't know	Don't know
Effect on human and animal overall well- being	Don't know	Don't know



AMR is a One World challenge





Conclusions: 1

- Animal agriculture uses more AM than human health does and is rapidly trending up
- Most use and most growth in use is in LMIC
- Dual challenge: access as well as excess
- AMR is not the only externality of disease in LMIC and trade-offs need to be examined
- Evidence should under-pin a business case but is mostly lacking for LMIC
- Yet there is a strong rationale for One Health as the best approach for solving cross-sectoral challenges





Antimicrobial Resistance Hub

www.amr.cgiar.org

Launched during partner event, 21/22 February in Nairobi



AMR in the CGIAR: Activity focus



